



北醫大健康數據服務

報告人: 許明暉 數據長

111年02月22日

北醫大數據處架構



數據處組織架構



石瑜講座教授




許明暉



張詠淳




陳錦華



徐之昇



陳錦華



簡麗年



張資昊

Biomarker開發三步驟





美國TCGA資料庫	北醫大聯合人體生物資料庫 (TMU-JBB)	北醫三院臨床試驗
<ul style="list-style-type: none">• 包含逾11,000例癌症患者資料• open data source• 目的：概念驗證(POC)	<ul style="list-style-type: none">• 組織庫臨床血漿檢體、臨床資料(病患基本資料、影像資料、生化數值、過去病史資料)• 目的：台灣人個案臨床檢體驗證	<ul style="list-style-type: none">• 查驗型臨床試驗• 經費成本高• 目的：產品上市準備• 維致生醫、籌備中新創公司

- 大腸直腸癌、乳癌、胰臟癌已有初步成果。

血液游離核酸甲基化指標作為乳癌伴隨式診斷產品

- 透過團隊新開發之游離核酸萃取技術、化學修飾、全基因體甲基化分析、挑選新穎具潛力生物指標(與子計畫一合作)
- 進行前瞻500例之臨床前試驗及來驗證其檢測結果，以開發出精準乳癌輔助伴隨式診斷工具(與子計畫一、三合作)
- 開發指標平台、提供治療期間動態預測體內腫瘤整體分子狀態，即時之精準預測用藥成效報告，作為臨床用藥前之重要治療參考 (LDTS / IVD)





*每名個案所接受之治療方式均分別計數; 全死因存活率追蹤至2020/4/30止。
 **以上僅供申請IRB參考用; 另如需客製化查詢, 請填寫線上諮詢單PICOTS。


參與國際研究數據聯盟OHDSI



- >300 collaborators from 30 different countries
- Experts in informatics, statistics, epidemiology, clinical sciences
- Active participation from academia, government, industry, providers
- Records on about 600 million unique patients in >100 databases



Tools to help you map data



OHDSI tools built to help

WhiteRabbit:
profile your source data

RabbitInAHat:
map your source structure to CDM tables and fields

ATHENA:
standardized vocabularies for all CDM domains

Usagi:
map your source codes to CDM vocabulary

CDM:
DDL, index, constraints for Oracle, SQL Server, PostgreSQL; Vocabulary tables with loading scripts

ACHILLES:
profile your CDM data; review data quality assessment; explore population-level summaries

OHDSI Forums:

Public discussions for OMOP CDM Implementers/developers

FW: JAMA Network Open JNO21-9758R Decision Letter

Dear all,

I am happy to let you know that our OHDSI hypertension paper, entitled "**Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort**" has been accepted for publication in JAMA Network Open. Please see below for the decision letter from the journal. We should receive the proof of this article in the next 4-6 weeks, and I will send it to you for review upon receipt.

Thank you again for your contributions to this important work. It is a privilege to be able to work with you all.

Best,
Yuan

H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection

Yu-Chuan Shen, MD¹; Hui-Ching Hsu, MD^{1,2}; Tzu-Min Lin, MD^{2,3}; Yu-Sheng Chang, MD^{2,4}; Li-Fang Hu, MD³; Lung-Fang Chen, MD^{1,2}; Sheng-Hong Lin, MD^{2,4}; Pei-I. Kuo, MD⁵; Wei-Sheng Chen, MD⁶; Yi-Chun Lin, MS⁷; Jin-Hua Chen, PhD^{7,8}; Yu-Chih Liang, PhD^{9,10,11}; and Chi-Ching Chang, PhD^{2,3}

- 大數據所陳錦華老師論文(co-corresponding author)被Journal of Clinical Oncology期刊接受
- **IF=44.544**，期刊排名：Journal of Clinical Oncology **Q1 (4/242)**
- 投稿論文題目：H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients with HBV, HCV, or Dual HBV-HCV Infection.

~提供優質生技醫療數據加值服務，共同邁向精準健康目標~

- 世界大學排名全國第二
- 11學院、15科系、45研究所



聯絡方式：鄭吉村執行秘書(Tel)02-66382736#1124; (e-mail) ahas4754@tmu.edu.tw

感謝聆聽
敬請指教